患有代谢功能障碍相关的脂肪肝疾病的儿童肺功能改变的危险因素
Sen-Mao Xu1,2, Shu-Qin Wang3, Yao Xu4,5
1Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. dxsm82@163.com.
患有代谢功能障碍相关的脂肪肝疾病 (MAFLD) 的儿童显示出独立于BMI的小呼吸道功能受损. 胰岛素抵抗和IL-1β是这种肺功能障碍的关键危险因素.
科学领域:
- 儿科肺病学 儿科肺病学
- 肝病学 肝病学是一种肝病学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 与代谢功能障碍相关的脂肪肝疾病 (MAFLD) 在儿童中越来越多地被诊断出.
- 儿科MAFLD的肺功能异常被怀疑但不清楚,特别是它们与BMI的独立性.
- 在这个人群中,肺功能受损的危险因素需要进一步阐明.
研究的目的:
- 与对照组相比,研究超重/肥胖儿童患有MAFLD的肺功能参数.
- 要确定肺功能异常是否独立于体重指数 (BMI).
- 确定与儿科MAFLD异常肺功能相关的危险因素,包括代谢和炎症标志物.
主要方法:
- 对40名患有MAFLD的超重/肥胖儿童和30名对照人的比较研究.
- 评估肺功能参数 (FVC,PEF,FEV1/FVC,FEF50,FEF75,MMEF) 和人类测量.
- 分析肝功能,脂质/葡萄糖代谢 (HOMA-IR) 和细胞因子水平 (IL-1β).
- 多变量回归分析以确定异常肺功能风险因素.
主要成果:
- 在MAFLD和对照组之间BMI没有显著差异.
- 患有MAFLD的儿童表现出较高的FVC,但较低的PEF,FEV1/FVC,FEF50,FEF75和MMEF.
- 胰岛素耐药性 (HOMA-IR) 与FEF25,FEF50和FEF75.5相反相关.
- 升高的IL-1β水平与MMEF和FEF50.0负相关.
结论:
- 儿科MAFLD与肺功能变化有关,包括独立于BMI的小呼吸道功能受损.
- HOMA-IR和升高的IL-1β是导致MAFLD儿童小气道功能异常的重要危险因素.
- 这些发现突显了MAFLD对儿童呼吸系统健康的系统影响,并强调了综合管理的必要性.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
相关概念视频
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
